



C-RADS Score for CT Colonography - Final Report

Patient Information

Identification Data		Extra Colonic	
HRN:	CRX0000001	Findings:	Yes
ID Card:	Unknown	Gallbladder:	Unknown
		Gastric:	Unknown
Personal Data		Liver:	Cirrhosis
Gender:	Male	Lungs:	Unknown
Age:	72	Lymphatics:	Unknown
		Ovarian:	Unknown
Polyps		Pancreatic:	Unknown
Findings:	Yes, several Polyps	Prostate:	Unknown
Morphology:	Unknown	Renal:	Unknown
Polyp Size (mm):	Unknown	Skeletal:	Unknown
Attenuation:	Unknown	Spleen:	Unknown
Location:	Unknown	Uterine:	Unknown
Polyps smaller or equal to 6 mm: 4		Vascular:	Unknown
Polyps between 6 and 9 mm: 2			
Polyps bigger than 9 mm: 2		CT Colonography Realization	
		Date:	02-03-2017
Masses			
Likely Malignant:	Yes		

Outcome

Results

According to CT Colonography Information, there is a HIGH RISK (C-RADS Score = 4) of having COLORECTAL CANCER.



Comments

Potentially Important Extra Colonic Finding (Extra Colonic Score = E4). Communicate to referring physician as per accepted practice guidelines.

Conclusions

WE HIGHLY RECOMMEND SURGICAL CONSULTATION FOR AN ENDOSCOPIC BIOPSY, PURSUANT TO THE CT COLONOGRAPHY IMAGING REPORT AND DATABASE SYSTEM (C-RADS). MOREOVER, EXTRA COLONIC E4 SCORE MAY SUGGEST TO COMMUNICATE TO REFERRING PHYSICIAN AS PER ACCEPTED PRACTICE GUIDELINES.

Bioprognos SL Benet Mateu, 40 - 08034 Barcelona (Spain) Email: info@bioprognos.com Website: www.bioprognos.com Technical Responsible Lorena Lendinez Chief Scientific Officer Bioprognos SL





This report has been generated from the data entered on 06-03-2017 13:36:18 UTC/GMT.

Disclaimer

Bioprognos has not developed the CT Colonography Imaging Report and Database System (C-RADS). C-RADS was developed in 2005 by the American College of Radiology (ACR) as a method -based in BI-RADS scheme for Breast Cancer evaluation-, to help in radiology findings classification. It mission is to standardize the terminology and the systematic for the radiological report, by defining standard terms of lesion morphology along with lesion size and number, an overall category of disease severity may be assigned per patient, as well as assign the attitude that should be taken in each case. Beyond clarity of communication to referring physicians, this scheme also provides the foundation to better evaluate results in clinical research across different centers. Bioprognos has implemented it for training or educational purposes only. You assume total responsibility for your use.



Bioprognos SL Benet Mateu, 40 - 08034 Barcelona (Spain) Email: info@bioprognos.com Website: www.bioprognos.com